fenofibrate has been researched along with Hyperinsulinism in 6 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Hyperinsulinism: A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of our study was to explore the changes in circulating Pref-1 concentrations in female subjects with obesity (OB) (n=19), females with obesity and type 2 diabetes mellitus (T2DM) (n=22), and sex- and age-matched healthy control subjects (C) (n=22), and to study its modulation by very low calorie diet (VLCD), acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp, and 3 months' treatment with PPAR-α agonist fenofibrate." | 9.17 | Serum preadipocyte factor-1 concentrations in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment. ( Drapalova, J; Haluzik, M; Haluzikova, D; Kavalkova, P; Lacinova, Z; Matoulek, M; Mraz, M; Novak, D; Roubicek, T; Touskova, V; Trachta, P; Urbanova, M, 2013) |
| "This randomized controlled study investigated metformin and fenofibrate, compared with metformin alone, for the treatment of peripheral insulin resistance in patients with simple obesity with hyperinsulinaemia but not diabetes." | 9.15 | Combination therapy with metformin and fenofibrate for insulin resistance in obesity. ( Li, XM; Li, Y; Shi, YQ; Xie, YH; Zhang, NN, 2011) |
| " The aim of our study was to explore the changes in circulating Pref-1 concentrations in female subjects with obesity (OB) (n=19), females with obesity and type 2 diabetes mellitus (T2DM) (n=22), and sex- and age-matched healthy control subjects (C) (n=22), and to study its modulation by very low calorie diet (VLCD), acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp, and 3 months' treatment with PPAR-α agonist fenofibrate." | 5.17 | Serum preadipocyte factor-1 concentrations in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment. ( Drapalova, J; Haluzik, M; Haluzikova, D; Kavalkova, P; Lacinova, Z; Matoulek, M; Mraz, M; Novak, D; Roubicek, T; Touskova, V; Trachta, P; Urbanova, M, 2013) |
| "This randomized controlled study investigated metformin and fenofibrate, compared with metformin alone, for the treatment of peripheral insulin resistance in patients with simple obesity with hyperinsulinaemia but not diabetes." | 5.15 | Combination therapy with metformin and fenofibrate for insulin resistance in obesity. ( Li, XM; Li, Y; Shi, YQ; Xie, YH; Zhang, NN, 2011) |
| "Metabolic syndrome is associated with increased cardiovascular risk." | 2.41 | [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. ( Idzior-Waluś, B, 2001) |
| "The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp (n=11 for T2DM and 10 for C), very-low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-alpha agonist fenofibrate (n=11 for T2DM)." | 1.37 | Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. ( Drápalová, J; Haluzík, M; Haluzíková, D; Hanušová, V; Kaválková, P; Lacinová, Z; Mráz, M; Trachta, P, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kavalkova, P | 2 |
| Touskova, V | 1 |
| Roubicek, T | 1 |
| Trachta, P | 2 |
| Urbanova, M | 1 |
| Drapalova, J | 2 |
| Haluzikova, D | 2 |
| Mraz, M | 2 |
| Novak, D | 1 |
| Matoulek, M | 1 |
| Lacinova, Z | 2 |
| Haluzik, M | 2 |
| Bougarne, N | 2 |
| Paumelle, R | 2 |
| Caron, S | 1 |
| Hennuyer, N | 1 |
| Mansouri, R | 1 |
| Gervois, P | 1 |
| Staels, B | 2 |
| Haegeman, G | 2 |
| De Bosscher, K | 2 |
| Hanušová, V | 1 |
| Li, XM | 1 |
| Li, Y | 1 |
| Zhang, NN | 1 |
| Xie, YH | 1 |
| Shi, YQ | 1 |
| Idzior-Waluś, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "FGF19 in Obstructive Cholestasis: Unveil the Signal"[NCT05718349] | 81 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fenofibrate and Hyperinsulinism
| Article | Year |
|---|---|
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemi | 2001 |
2 trials available for fenofibrate and Hyperinsulinism
| Article | Year |
|---|---|
Serum preadipocyte factor-1 concentrations in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment.
Topics: Anthropometry; Body Weight; Calcium-Binding Proteins; Caloric Restriction; Diabetes Mellitus, Type 2 | 2013 |
Combination therapy with metformin and fenofibrate for insulin resistance in obesity.
Topics: Adult; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; | 2011 |
3 other studies available for fenofibrate and Hyperinsulinism
| Article | Year |
|---|---|
PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB.
Topics: Animals; Cell Line, Tumor; Dietary Fats; Fenofibrate; Gene Expression; Glucocorticoids; Hepatocytes; | 2009 |
Circumventing glucocorticoid-mediated hyperinsulinemia via the activation of PPARalpha.
Topics: Fenofibrate; Gene Expression; Glucocorticoids; Humans; Hyperinsulinism; Hypolipidemic Agents; Neopla | 2009 |
Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment.
Topics: Acute Disease; Adult; Biomarkers; Blood Glucose; Caloric Restriction; Diabetes Mellitus, Type 2; Fem | 2011 |